Hikma Pharma Offers Up To $300M For Injectables Biz
London-based Hikma Pharmaceuticals PLC agreed to buy out Ben Venue Laboratories Inc.'s injectables business and a troubled manufacturing facility in Ohio for $300 million in cash, the drugmakers said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article